Market Cap 13.12B
Revenue (ttm) 0.00
Net Income (ttm) -221.32M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 1,211,688
Avg Vol 3,062,404
Day's Range N/A - N/A
Shares Out 771.15M
Stochastic %K 50%
Beta -1.53
Analysts Strong Sell
Price Target $32.31

Company Profile

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Industry: Biotechnology
Sector: Healthcare
Phone: 305 203 2034
Address:
601 Brickell Key Drive, Suite 1000, Miami, United States
BigBeardTrader
BigBeardTrader Dec. 11 at 7:15 PM
$BMEA added 10k shares on top of my 30k. One of the most misunderstood and undervalued biotech names currently. $SMMT is the other.
1 · Reply
SmokeWagon
SmokeWagon Dec. 11 at 6:18 PM
0 · Reply
TruthBroker2
TruthBroker2 Dec. 11 at 5:28 PM
0 · Reply
BigBeardTrader
BigBeardTrader Dec. 11 at 4:43 PM
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 1:42 PM
$SMMT has already delivered a massive run — up more than 700% in the past two years — yet analysts still see upside from here. So why does Wall Street remain this bullish? 👀 Much of the conviction comes down to ivonescimab’s momentum. Despite the stock drifting near its 52-week low, recent Phase 3 HARMONi-A results from partner Akeso injected new confidence into the story: • Median OS: 16.8 vs. 14.1 months for chemo alone • HR = 0.74 — the first ivonescimab regimen to deliver a statistically significant OS win in Phase 3 • Reinforces the strength of Summit’s global HARMONi program, which has already hit its PFS endpoint and showed an encouraging OS trend With FDA discussions coming up and sentiment stabilizing, the current weakness may be less about fundamentals — and more about timing. Is $SMMT setting up for another leg higher? See where Wall Street thinks this is headed 👇 https://www.zacks.com/stock/research/SMMT/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-24371&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_24371
0 · Reply
ChillPill1972
ChillPill1972 Dec. 11 at 2:09 AM
$SMMT Akeso PR: Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025 Published: 12.10.25 The (ORR) for the overall population was 80%, the disease control rate was 100%, and the median duration of response was 12.2 months; the median progression-free survival was 15.2 mo., with a 12-mo. PFS rate of 56.3%. In the CPS>=10 subgroup, the ORR was 83.3%, the DCR was 100%, the mDOR was 12.2 mo.; the mPFS was 15.9 months, with a 12-month PFS rate of 66.7%. In the CPS<10 subgroup, the ORR was 79.3%, the DCR was 100%, the mDOR was 9.9 mo.; the mPFS was 13.04 mo., with a 12-month PFS rate of 54.3%. -- In the CPS>=1 subgroup, the ORR was 72.2%, the DCR was 100%, the mDOR was 12.2 mo.; the mPFS was 15.9 mo., with a 12-month PFS rate of 63.8%. Overall survival data is not yet mature. Ivonescimab combined with chemotherapy as first-line treatment for TNBC demonstrated a good safety profile. No TRAEs led to discontinuation or death in this study.
0 · Reply
TruthBroker2
TruthBroker2 Dec. 11 at 1:35 AM
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 10 at 11:25 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $OPAD | Timeframe: 6M / 1D Market Cap: $71.51M • Pattern score: 0.67 • Current price: $1.940 • Peak (window): $6.230 • Trough (post-spike): $1.680 • Pullback: ~73.0% from peak • Move off lows: ~31.1% of peak Stock Plan (educational only) • Entry zone: $1.882 – $1.979 • Scalp target: $2.095 → Est. ROI: ~8.0% • Swing target: $3.104 → Est. ROI: ~60.0% • Protective stop: $1.649 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-09 • Example Strike: ~$2.000 (≈5% OTM) • Example Premium (entry): ~$0.240 → Exit target: ~$0.420 (≈+75% vs entry) → Protective stop: ~$0.144 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $SMMT
0 · Reply
HawkSqueezers
HawkSqueezers Dec. 10 at 8:12 PM
Could SBDS be todays top micro float runner?! Looks like ticker SBDS could HALT UP again ! It's getting a lot of attention Only 700k shares outstanding - We have seen parabolic runs on these mico floats recently. Don't miss SBDS - It's starting to SQUEEZE up $BBGI $PATH $MBOT $SMMT insider
1 · Reply
BigFishLittleBish
BigFishLittleBish Dec. 10 at 6:45 PM
$SMMT Maybe you should be listening to the most recent conferences then.
0 · Reply
Latest News on SMMT
Don't Buy Summit Therapeutics Until This Big Thing Happen

Dec 3, 2025, 4:44 AM EST - 8 days ago

Don't Buy Summit Therapeutics Until This Big Thing Happen


2 Monster Stocks in the Making to Buy and Hold

Dec 2, 2025, 7:00 AM EST - 9 days ago

2 Monster Stocks in the Making to Buy and Hold

SOFI


Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying

Nov 19, 2025, 4:26 AM EST - 22 days ago

Summit: A Cautious Bet Backed By Anti-VEGF & Insider Buying


1 Monster Stock in the Making to Buy and Hold

Oct 27, 2025, 5:51 AM EDT - 6 weeks ago

1 Monster Stock in the Making to Buy and Hold


Summit Therapeutics: A Risky Bet in the Biotech Arena?

Oct 24, 2025, 7:00 PM EDT - 6 weeks ago

Summit Therapeutics: A Risky Bet in the Biotech Arena?


Summit Therapeutics Raises $500 Million in Private Placement

Oct 22, 2025, 8:00 AM EDT - 7 weeks ago

Summit Therapeutics Raises $500 Million in Private Placement


Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold

Oct 20, 2025, 2:35 PM EDT - 7 weeks ago

Summit's Bold BLA Without Stat-Sig OS: Why I Step Back To Hold


What's Going On With Summit Therapeutics Stock On Monday?

Oct 20, 2025, 10:05 AM EDT - 7 weeks ago

What's Going On With Summit Therapeutics Stock On Monday?


Ten Bull Market 10-Baggers

Sep 22, 2025, 2:45 PM EDT - 2 months ago

Ten Bull Market 10-Baggers

APP CVNA FTAI HOOD MSTR NVDA PLTR


Summit Therapeutics Inc. Investigated by the Portnoy Law Firm

Sep 16, 2025, 4:31 PM EDT - 3 months ago

Summit Therapeutics Inc. Investigated by the Portnoy Law Firm


Top 3 Health Care Stocks You'll Regret Missing In Q3

Sep 9, 2025, 9:12 AM EDT - 3 months ago

Top 3 Health Care Stocks You'll Regret Missing In Q3

LNAI


Is Summit Therapeutics a Buy, Sell, or Hold Now?

Sep 9, 2025, 5:51 AM EDT - 3 months ago

Is Summit Therapeutics a Buy, Sell, or Hold Now?


Summit Therapeutics (SMMT) WCLC Update Call (Transcript)

Sep 8, 2025, 3:36 PM EDT - 3 months ago

Summit Therapeutics (SMMT) WCLC Update Call (Transcript)


3 No-Brainer Stocks to Buy Right Now

Aug 31, 2025, 6:45 AM EDT - 3 months ago

3 No-Brainer Stocks to Buy Right Now

PFE VRTX


3 Fantastic Growth Stocks to Buy in August

Aug 17, 2025, 6:42 AM EDT - 4 months ago

3 Fantastic Growth Stocks to Buy in August

LLY VRTX


3 Monster Stocks in the Making to Buy Right Now

Jul 21, 2025, 12:07 AM EDT - 5 months ago

3 Monster Stocks in the Making to Buy Right Now

CRSP VKTX


Why Summit Therapeutics Stock Soared 8% Higher Today

Jul 3, 2025, 3:50 PM EDT - 5 months ago

Why Summit Therapeutics Stock Soared 8% Higher Today


BigBeardTrader
BigBeardTrader Dec. 11 at 7:15 PM
$BMEA added 10k shares on top of my 30k. One of the most misunderstood and undervalued biotech names currently. $SMMT is the other.
1 · Reply
SmokeWagon
SmokeWagon Dec. 11 at 6:18 PM
0 · Reply
TruthBroker2
TruthBroker2 Dec. 11 at 5:28 PM
0 · Reply
BigBeardTrader
BigBeardTrader Dec. 11 at 4:43 PM
0 · Reply
ZacksResearch
ZacksResearch Dec. 11 at 1:42 PM
$SMMT has already delivered a massive run — up more than 700% in the past two years — yet analysts still see upside from here. So why does Wall Street remain this bullish? 👀 Much of the conviction comes down to ivonescimab’s momentum. Despite the stock drifting near its 52-week low, recent Phase 3 HARMONi-A results from partner Akeso injected new confidence into the story: • Median OS: 16.8 vs. 14.1 months for chemo alone • HR = 0.74 — the first ivonescimab regimen to deliver a statistically significant OS win in Phase 3 • Reinforces the strength of Summit’s global HARMONi program, which has already hit its PFS endpoint and showed an encouraging OS trend With FDA discussions coming up and sentiment stabilizing, the current weakness may be less about fundamentals — and more about timing. Is $SMMT setting up for another leg higher? See where Wall Street thinks this is headed 👇 https://www.zacks.com/stock/research/SMMT/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-24371&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_24371
0 · Reply
ChillPill1972
ChillPill1972 Dec. 11 at 2:09 AM
$SMMT Akeso PR: Updated Efficacy Data of Ivonescimab Combined with Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025 Published: 12.10.25 The (ORR) for the overall population was 80%, the disease control rate was 100%, and the median duration of response was 12.2 months; the median progression-free survival was 15.2 mo., with a 12-mo. PFS rate of 56.3%. In the CPS>=10 subgroup, the ORR was 83.3%, the DCR was 100%, the mDOR was 12.2 mo.; the mPFS was 15.9 months, with a 12-month PFS rate of 66.7%. In the CPS<10 subgroup, the ORR was 79.3%, the DCR was 100%, the mDOR was 9.9 mo.; the mPFS was 13.04 mo., with a 12-month PFS rate of 54.3%. -- In the CPS>=1 subgroup, the ORR was 72.2%, the DCR was 100%, the mDOR was 12.2 mo.; the mPFS was 15.9 mo., with a 12-month PFS rate of 63.8%. Overall survival data is not yet mature. Ivonescimab combined with chemotherapy as first-line treatment for TNBC demonstrated a good safety profile. No TRAEs led to discontinuation or death in this study.
0 · Reply
TruthBroker2
TruthBroker2 Dec. 11 at 1:35 AM
0 · Reply
SimpleWinningSetups
SimpleWinningSetups Dec. 10 at 11:25 PM
📈 Simple Winning Setups – Simple Winning Setup Detected Ticker: $OPAD | Timeframe: 6M / 1D Market Cap: $71.51M • Pattern score: 0.67 • Current price: $1.940 • Peak (window): $6.230 • Trough (post-spike): $1.680 • Pullback: ~73.0% from peak • Move off lows: ~31.1% of peak Stock Plan (educational only) • Entry zone: $1.882 – $1.979 • Scalp target: $2.095 → Est. ROI: ~8.0% • Swing target: $3.104 → Est. ROI: ~60.0% • Protective stop: $1.649 → Risk: ~15.0% below current Options Idea (real chain data only) • Type: Call | Example Exp: 2026-01-09 • Example Strike: ~$2.000 (≈5% OTM) • Example Premium (entry): ~$0.240 → Exit target: ~$0.420 (≈+75% vs entry) → Protective stop: ~$0.144 (≈-40% vs entry) • Structure: single swing call, risk defined by your stock-level stop. This is an automated pattern alert from Simple Winning Setups. For education & research only – not financial advice. https://www.simplewinningsetups Trending Ticker Watch: $SMMT
0 · Reply
HawkSqueezers
HawkSqueezers Dec. 10 at 8:12 PM
Could SBDS be todays top micro float runner?! Looks like ticker SBDS could HALT UP again ! It's getting a lot of attention Only 700k shares outstanding - We have seen parabolic runs on these mico floats recently. Don't miss SBDS - It's starting to SQUEEZE up $BBGI $PATH $MBOT $SMMT insider
1 · Reply
BigFishLittleBish
BigFishLittleBish Dec. 10 at 6:45 PM
$SMMT Maybe you should be listening to the most recent conferences then.
0 · Reply
HawkSqueezers
HawkSqueezers Dec. 10 at 6:39 PM
Could SBDS be todays top micro float runner?! Looks like ticker SBDS could HALT UP again ! It's getting a lot of attention Only 700k shares outstanding - We have seen parabolic runs on these mico floats recently. Don't miss SBDS - It's starting to SQUEEZE up $DPRO $SBET $ENPH $SMMT DVV
0 · Reply
HawkSqueezers
HawkSqueezers Dec. 10 at 6:34 PM
Could SBDS be todays top micro float runner?! Looks like ticker SBDS could HALT UP again ! It's getting a lot of attention Only 700k shares outstanding - We have seen parabolic runs on these mico floats recently. Don't miss SBDS - It's starting to SQUEEZE up $WULF $WOLF $MBOT $SMMT 0c2
1 · Reply
Addallelectric
Addallelectric Dec. 10 at 6:06 PM
$SMMT everyone ready for take off?
0 · Reply
SmokeWagon
SmokeWagon Dec. 10 at 3:34 PM
0 · Reply
Sellasgps26BAT10
Sellasgps26BAT10 Dec. 10 at 3:18 PM
$ABVX $SLS $SMMT 👇 ✌️🙏❤️‍🩹🌲
2 · Reply
Sellasgps26BAT10
Sellasgps26BAT10 Dec. 10 at 2:49 PM
$ABVX $SLS $SMMT ABVX from $2.00 pre data to $135.00+ before BO rumors. Sellas next up! ✌️🙏❤️‍🩹🌲
2 · Reply
Magic8BallResponse
Magic8BallResponse Dec. 10 at 1:37 PM
$SMMT Needs western data. Can't see it moving without it
0 · Reply
ZacksResearch
ZacksResearch Dec. 10 at 1:10 PM
$SMMT is hovering near its 52-week low — but the fundamentals may be starting to turn. Is this a buy-the-dip setup? 🤔 After a sharp September selloff tied to concerns over East/West efficacy gaps, new Phase 3 HARMONi-A data from partner Akeso materially shifted the narrative: • Ivonescimab + chemo improved OS to 16.8 vs. 14.1 months • HR = 0.74 (p=0.019) — the first ivonescimab regimen to achieve a statistically significant OS win in Phase 3 ✅ • Strengthens confidence in Summit’s global HARMONi program, which already met its PFS primary endpoint and showed a favorable OS trend With FDA discussions ahead and valuation near cycle lows, the stock’s pullback may be masking improving clinical momentum 👀 See where Wall Street sees $SMMT headed 👇 https://www.zacks.com/stock/research/SMMT/price-target-stock-forecast?cid=sm-stocktwits-0-price_target-teaser-24141&ADID=SYND_STOCKTWITS_TWEET_0_PRICETARGET_TEASER_24141
0 · Reply
cled
cled Dec. 10 at 11:16 AM
0 · Reply
TruthBroker2
TruthBroker2 Dec. 10 at 10:42 AM
0 · Reply
MoneyGroupLLC
MoneyGroupLLC Dec. 10 at 10:36 AM
Enter: $SMMT Calls Strike Price: $18 Expiry Date: JAN 02 2026 Buy in Price: $2.28 - $3.30 Sell Price: $3.56 Profit : +56% (Turn every $1 into $1.56) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
profitraider
profitraider Dec. 10 at 1:28 AM
$SMMT Sumthin don’t look right with this stock!
0 · Reply